AI replacing animal experiments? A message from the FDA has left "monkey breeders" feeling devastated, and experts state that "we are still far from the stage of implementation."
① The news that the USA FDA has publicly stated it will gradually replace animal testing requirements has led to an increase in the stock prices of AI pharmaceutical companies, impacting traditional drug evaluation CRO companies; ② Some believe this action represents a trend in Industry development. However, others believe that it is far from being implementable.
Assertio to Participate in the IAccess Alpha Virtual Best Ideas Conference on March 25-26, 2025
Assertio Holdings Is Maintained at Buy by HC Wainwright & Co.
Assertio Holdings Analyst Ratings
Express News | Assertio Holdings, Inc. : H.c. Wainwright Cuts Target Price to $3.5 From $4
New Analyst Forecast: $ASRT Given $1.75 Price Target
The tariff war between the US and Europe is escalating, and Trump's 'tariff big stick' is making the pharmaceutical industry tremble.
Pharmaceutical companies are urging the Trump administration and EU officials to exclude Medical products from the escalation of the trade war.
New York Manufacturing Hits Low, Inflation Fears Rise
A. G. P. Maintains Assertio(ASRT.US) With Buy Rating, Cuts Target Price to $1.75
Assertio Holdings Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
Assertio Price Target Lowered to $1.75 From $2.15 at Alliance Global
Lake Street Maintains Assertio(ASRT.US) With Buy Rating, Maintains Target Price $3
Assertio Therapeutics' Earnings Call: Growth Amid Challenges
Q4 2024 Assertio Holdings Inc Earnings Call
Assertio Therapeutics (ASRT) Gets a Buy From Lake Street
Assertio Therapeutics Reports 2024 Financial Results
Earnings Call Summary | Assertio(ASRT.US) Q4 2024 Earnings Conference
Assertio | 10-K: FY2024 Annual Report
ASSERTIO THERAPEUTICS Earnings Results: $ASRT Reports Quarterly Earnings
Assertio: Q4 Earnings Snapshot